{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:04:59Z","timestamp":1766585099496,"version":"3.48.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK124182"],"award-info":[{"award-number":["R01 DK124182"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018283","name":"Fifth District Eagles Cancer Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011475","name":"Cholangiocarcinoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015724","name":"Center for Cell Signaling in Gastroenterology, Mayo Clinic","doi-asserted-by":"publisher","award":["P30DK084567"],"award-info":[{"award-number":["P30DK084567"]}],"id":[{"id":"10.13039\/100015724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-025-01133-x","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:25:24Z","timestamp":1766579124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-0226","authenticated-orcid":false,"given":"Muhammed Dogukan","family":"Aksu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayla T.","family":"Millender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal E.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan D.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-6184","authenticated-orcid":false,"given":"Jennifer A.","family":"Yonkus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EeeLN H.","family":"Buckarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan W.","family":"Werneburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-009X","authenticated-orcid":false,"given":"Gregory J.","family":"Gores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-056X","authenticated-orcid":false,"given":"Caitlin B.","family":"Conboy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"1133_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J. Clin. 71, 209\u2013249 (2021)","journal-title":"Ca-Cancer J. Clin."},{"key":"1133_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"J.L. Petrick, A.A. Florio, A. Znaor, D. Ruggieri, M. Laversanne, C.S. Alvarez, J. Ferlay, P.C. Valery, F. Bray, McGlynn, K. A. International trends in hepatocellular carcinoma incidence, 1978\u20132012. Int. J. Cancer. 147, 317\u2013330 (2020)","journal-title":"Int. J. Cancer"},{"key":"1133_CR3","first-page":"201","volume":"38","author":"SF Altekruse","year":"2011","unstructured":"S.F. Altekruse, S.S. Devesa, L.A. Dickie, K.A. McGlynn, D.E. Kleiner, Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J. Registry Manag. 38, 201\u2013205 (2011)","journal-title":"J. Registry Manag"},{"key":"1133_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hep.29789","volume":"68","author":"E Brunt","year":"2018","unstructured":"E. Brunt, S. Aishima, P.A. Clavien, K. Fowler, Z. Goodman, G. Gores, A. Gouw, A. Kagen, D. Klimstra, M. Komuta et al., cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 68, 113\u2013126 (2018)","journal-title":"Hepatology"},{"key":"1133_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/hep.32452","volume":"77","author":"M Komuta","year":"2023","unstructured":"M. Komuta, A. Ueno, M. Sakamoto, The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer. Hepatology. 77, 10\u201312 (2023)","journal-title":"Hepatology"},{"key":"1133_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/hep.32397","volume":"77","author":"Y Jeon","year":"2023","unstructured":"Y. Jeon, S.M. Kwon, H. Rhee, J.E. Yoo, T. Chung, H.G. Woo, Y.N. Park, Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma. Hepatology. 77, 92\u2013108 (2023)","journal-title":"Hepatology"},{"key":"1133_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"O. Clements, J. Eliahoo, J.U. Kim, S.D. Taylor-Robinson, S.A. Khan, Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J. Hepatol. 72, 95\u2013103 (2020)","journal-title":"J. Hepatol."},{"key":"1133_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MEG.0000000000001684","volume":"33","author":"S Corrao","year":"2021","unstructured":"S. Corrao, G. Natoli, C. Argano, Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis. Eur. J. Gastroenterol. Hepatol. 33, 62\u201368 (2021)","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"1133_CR9","doi-asserted-by":"crossref","unstructured":"N.N. Massarweh, H.B. El-Serag, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24, (2017)","DOI":"10.1177\/1073274817729245"},{"key":"1133_CR10","first-page":"4","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"K.A. McGlynn, J.L. Petrick, H.B. El-Serag, Epidemiol. Hepatocellular Carcinoma Hepatol. 73, 4\u201313 (2021)","journal-title":"Epidemiol. Hepatocellular Carcinoma Hepatol."},{"key":"1133_CR11","doi-asserted-by":"crossref","unstructured":"J. Kim, E. Seki, Inflammation and immunity in liver neoplasms: implications for future therapeutic strategies. Mol. Cancer Ther. 24, 188\u2013199 (2025)","DOI":"10.1158\/1535-7163.MCT-23-0726"},{"key":"1133_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.stem.2020.08.016","volume":"27","author":"VL Gadd","year":"2020","unstructured":"V.L. Gadd, N. Aleksieva, S.J. Forbes, Epithelial plasticity during liver injury and regeneration. Cell. Stem Cell. 27, 557\u2013573 (2020)","journal-title":"Cell. Stem Cell."},{"key":"1133_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tcb.2020.01.007","volume":"30","author":"WP Li","year":"2020","unstructured":"W.P. Li, L. Li, L.J. Hui, Cell plasticity in liver regeneration. Trends Cell. Biol. 30, 329\u2013338 (2020)","journal-title":"Trends Cell. Biol."},{"key":"1133_CR14","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.ajpath.2017.07.022","volume":"187","author":"M Yamamoto","year":"2017","unstructured":"M. Yamamoto, B. Xin, K. Watanabe, T. Ooshio, K. Fujii, X. Chen, Y. Okada, H. Abe, Y. Taguchi, N. Miyokawa et al., Oncogenic determination of a broad spectrum of phenotypes of Hepatocyte-Derived mouse liver tumors. Am. J. Pathol. 187, 2711\u20132725 (2017)","journal-title":"Am. J. Pathol."},{"key":"1133_CR15","doi-asserted-by":"crossref","unstructured":"G. Wang, Q. Wang, N. Liang, H.Y. Xue, T. Yang, X.G. Chen, Z.Y. Qiu, C. Zeng, T. Sun, W.T. Yuan et al., Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 11, (2020)","DOI":"10.1038\/s41419-020-2509-x"},{"key":"1133_CR16","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1242\/jcs.01169","volume":"117","author":"N Tanimizu","year":"2004","unstructured":"N. Tanimizu, A. Miyajima, Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J. Cell. Sci. 117, 3165\u20133174 (2004)","journal-title":"J. Cell. Sci."},{"key":"1133_CR17","doi-asserted-by":"crossref","unstructured":"A. Moeini, P.K. Haber, D. Sia, Cell of origin in biliary tract cancers and clinical implications. Jhep Rep. 3, (2021)","DOI":"10.1016\/j.jhepr.2021.100226"},{"key":"1133_CR18","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41388-018-0188-1","volume":"37","author":"J Wang","year":"2018","unstructured":"J. Wang, M. Dong, Z. Xu, X. Song, S. Zhang, Y. Qiao, L. Che, J. Gordan, K. Hu, Y. Liu et al., Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 37, 3229\u20133242 (2018)","journal-title":"Oncogene"},{"key":"1133_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1172\/JCI63212","volume":"122","author":"B Fan","year":"2012","unstructured":"B. Fan, Y. Malato, D.F. Calvisi, S. Naqvi, N. Razumilava, S. Ribback, G.J. Gores, F. Dombrowski, M. Evert, X. Chen et al., Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Invest. 122, 2911\u20132915 (2012)","journal-title":"J. Clin. Invest."},{"key":"1133_CR20","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1172\/JCI63065","volume":"122","author":"S Sekiya","year":"2012","unstructured":"S. Sekiya, A. Suzuki, Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J. Clin. Invest. 122, 3914\u20133918 (2012)","journal-title":"J. Clin. Invest."},{"key":"1133_CR21","doi-asserted-by":"publisher","first-page":"34691","DOI":"10.1038\/srep34691","volume":"6","author":"M Terada","year":"2016","unstructured":"M. Terada, K. Horisawa, S. Miura, Y. Takashima, Y. Ohkawa, S. Sekiya, K. Matsuda-Ito, A. Suzuki, Kupffer cells induce Notch-mediated hepatocyte conversion in a common mouse model of intrahepatic cholangiocarcinoma. Sci. Rep. 6, 34691 (2016)","journal-title":"Sci. Rep."},{"key":"1133_CR22","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1158\/0008-5472.CAN-17-1123","volume":"78","author":"MA Hill","year":"2018","unstructured":"M.A. Hill, W.B. Alexander, B. Guo, Y. Kato, K. Patra, M.R. O\u2019Dell, M.N. McCall, C.L. Whitney-Miller, N. Bardeesy, A.F. Hezel, Kras and Tp53 mutations cause Cholangiocyte- and Hepatocyte-Derived cholangiocarcinoma. Cancer Res. 78, 4445\u20134451 (2018)","journal-title":"Cancer Res."},{"key":"1133_CR23","doi-asserted-by":"crossref","unstructured":"Y. Saito, T. Nakaoka, T. Muramatsu, H. Ojima, A. Sukeda, Y. Sugiyama, R. Uchida, R. Furukawa, A. Kitahara, T. Sato et al., Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. Sci. Rep-Uk 8, (2018)","DOI":"10.1038\/s41598-018-21121-6"},{"key":"1133_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"T. Moroishi, C.G. Hansen, K.L. Guan, The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer. 15, 73\u201379 (2015)","journal-title":"Nat. Rev. Cancer"},{"key":"1133_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrd4161","volume":"13","author":"R Johnson","year":"2014","unstructured":"R. Johnson, G. Halder, The two faces of hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov. 13, 63\u201379 (2014)","journal-title":"Nat. Rev. Drug Discov"},{"key":"1133_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"K.F. Harvey, X.M. Zhang, D.M. Thomas, The Hippo pathway and human cancer. Nat. Rev. Cancer. 13, 246\u2013257 (2013)","journal-title":"Nat. Rev. Cancer"},{"key":"1133_CR27","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1158\/1078-0432.CCR-12-3172","volume":"19","author":"S Piccolo","year":"2013","unstructured":"S. Piccolo, M. Cordenonsi, S. Dupont, Molecular Pathways, YAP and TAZ take center stage in organ growth and tumorigenesis. Clin. Cancer Res. 19, 4925\u20134930 (2013)","journal-title":"Clin. Cancer Res."},{"key":"1133_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/bs.acr.2022.02.003","volume":"156","author":"S Ko","year":"2022","unstructured":"S. Ko, M. Kim, L. Molina, A.E. Sirica, S.P. Monga, YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma. Adv. Cancer Res. 156, 283\u2013317 (2022)","journal-title":"Adv. Cancer Res."},{"key":"1133_CR29","doi-asserted-by":"crossref","unstructured":"Van M. Haele, I.M. Moya, R. Karaman, G. Rens, J. Snoeck, O. Govaere, F. Nevens, C. Verslype, B. Topal, D. Monbaliu et al., YAP and TAZ heterogeneity in primary liver cancer: an analysis of its prognostic and diagnostic role. Int. J. Mol. Sci. 20, (2019)","DOI":"10.3390\/ijms20030638"},{"key":"1133_CR30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2014.06.033","volume":"61","author":"A Perra","year":"2014","unstructured":"A. Perra, M.A. Kowalik, E. Ghiso, G.M. Ledda-Columbano, Di L. Tommaso, M.M. Angioni, C. Raschioni, E. Testore, M. Roncalli, S. Giordano et al., YAP activation is an early event and a potential therapeutic target in liver cancer development. J. Hepatol. 61, 1088\u20131096 (2014)","journal-title":"J. Hepatol."},{"key":"1133_CR31","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1002\/cncr.24495","volume":"115","author":"MZ Xu","year":"2009","unstructured":"M.Z. Xu, T.J. Yao, N.P. Lee, I.O. Ng, Y.T. Chan, L. Zender, S.W. Lowe, R.T. Poon, J.M. Luk, Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115, 4576\u20134585 (2009)","journal-title":"Cancer"},{"key":"1133_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ceb.2019.07.006","volume":"61","author":"S Zhang","year":"2019","unstructured":"S. Zhang, D. Zhou, Role of the transcriptional coactivators YAP\/TAZ in liver cancer. Curr. Opin. Cell. Biol. 61, 64\u201371 (2019)","journal-title":"Curr. Opin. Cell. Biol."},{"key":"1133_CR33","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.27992","volume":"62","author":"P Marti","year":"2015","unstructured":"P. Marti, C. Stein, T. Blumer, Y. Abraham, M.T. Dill, M. Pikiolek, V. Orsini, G. Jurisic, P. Megel, Z. Makowska et al., YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology. 62, 1497\u20131510 (2015)","journal-title":"Hepatology"},{"key":"1133_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3727\/105221619X15617324583639","volume":"20","author":"N Werneburg","year":"2020","unstructured":"N. Werneburg, G.J. Gores, R.L. Smoot, The Hippo pathway and YAP signaling: emerging concepts in Regulation, Signaling, and experimental targeting strategies with implications for hepatobiliary malignancies. Gene Expr. 20, 67\u201374 (2020)","journal-title":"Gene Expr."},{"key":"1133_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12885-017-3431-1","volume":"17","author":"K Lee","year":"2017","unstructured":"K. Lee, K.B. Lee, H.Y. Jung, N.J. Yi, K.W. Lee, K.S. Suh, J.J. Jang, The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas. BMC Cancer. 17, 441 (2017)","journal-title":"BMC Cancer"},{"key":"1133_CR36","doi-asserted-by":"publisher","first-page":"13499","DOI":"10.1007\/s13277-016-5211-y","volume":"37","author":"H Wu","year":"2016","unstructured":"H. Wu, Y. Liu, X.W. Jiang, W.F. Li, G. Guo, J.P. Gong, X. Ding, Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. Tumour Biol. 37, 13499\u201313508 (2016)","journal-title":"Tumour Biol."},{"key":"1133_CR37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.cels.2018.05.006","volume":"6","author":"N Ege","year":"2018","unstructured":"N. Ege, A.M. Dowbaj, M. Jiang, M. Howell, S. Hooper, C. Foster, R.P. Jenkins, E. Sahai, Quantitative analysis reveals that actin and Src-Family kinases regulate nuclear YAP1 and its export. Cell. Syst. 6, 692\u2013 (2018)","journal-title":"Cell. Syst."},{"key":"1133_CR38","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","volume":"94","author":"S Piccolo","year":"2014","unstructured":"S. Piccolo, S. Dupont, M. Cordenonsi, The biology of Yap\/Taz: Hippo signaling and beyond. Physiol. Rev. 94, 1287\u20131312 (2014)","journal-title":"Physiol. Rev."},{"key":"1133_CR39","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/1541-7786.MCR-18-0158","volume":"16","author":"T Sugihara","year":"2018","unstructured":"T. Sugihara, N.W. Werneburg, M.C. Hernandez, L. Yang, A. Kabashima, P. Hirsova, L. Yohanathan, C. Sosa, M.J. Truty, G. Vasmatzis et al., YAP tyrosine phosphorylation and nuclear localization in cholangiocarcinoma cells are regulated by LCK and independent of LATS activity. Mol. Cancer Res. 16, 1556\u20131567 (2018)","journal-title":"Mol. Cancer Res."},{"key":"1133_CR40","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jcb.26246","volume":"119","author":"RL Smoot","year":"2018","unstructured":"R.L. Smoot, N.W. Werneburg, T. Sugihara, M.C. Hernandez, L. Yang, C. Mehner, R.P. Graham, S.F. Bronk, M.J. Truty, G.J. Gores, Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. J. Cell. Biochem. 119, 824\u2013836 (2018)","journal-title":"J. Cell. Biochem."},{"key":"1133_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"K. Taniguchi, L.W. Wu, S.I. Grivennikov, de P.R. Jong, I. Lian, F.X. Yu, K.P. Wang, S.B. Ho, B.S. Boland, J.T. Chang et al., A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 519, 57\u2013U107 (2015)","journal-title":"Nature"},{"key":"1133_CR42","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1074\/jbc.RA118.004364","volume":"294","author":"JM Lamar","year":"2019","unstructured":"J.M. Lamar, Y. Xiao, E. Norton, Z.G. Jiang, G.M. Gerhard, S. Kooner, J.S.A. Warren, R. Hynes, O. SRC tyrosine kinase activates the YAP\/TAZ axis and thereby drives tumor growth and metastasis. J. Biol. Chem. 294, 2302\u20132317 (2019)","journal-title":"J. Biol. Chem."},{"key":"1133_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2022.09.014","volume":"78","author":"CB Conboy","year":"2023","unstructured":"C.B. Conboy, J.A. Yonkus, E.L.N.H. Buckarma, D.G. Mun, N.W. Werneburg, R.D. Watkins, R. Alva-Ruiz, J.L. Tomlinson, Y. Guo, J. Wang et al., LCK Inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma. J. Hepatol. 78, 142\u2013152 (2023)","journal-title":"J. Hepatol."},{"key":"1133_CR44","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/hep.27687","volume":"61","author":"D Yamada","year":"2015","unstructured":"D. Yamada, S. Rizvi, N. Razumilava, S.F. Bronk, J.I. Davila, M.D. Champion, M.J. Borad, J.A. Bezerra, X. Chen, G.J. Gores, IL-33 facilitates Oncogene-Induced cholangiocarcinoma in mice by an Interleukin-6-Sensitive mechanism. Hepatology. 61, 1627\u20131642 (2015)","journal-title":"Hepatology"},{"key":"1133_CR45","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/nprot.2007.471","volume":"2","author":"JB Bell","year":"2007","unstructured":"J.B. Bell, K.M. Podetz-Pedersen, E.L. Aronovich, L.R. Belur, R.S. McIvor, P.B. Hackett, Preferential delivery of the transposon system to livers of mice by hydrodynamic injection. Nat. Protoc. 2, 3153\u20133165 (2007)","journal-title":"Nat. Protoc."},{"key":"1133_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/dvg.20335","volume":"45","author":"MD Muzumdar","year":"2007","unstructured":"M.D. Muzumdar, B. Tasic, K. Miyamichi, L. Li, Luo, L. A global double-fluorescent Cre reporter mouse. Genesis. 45, 593\u2013605 (2007)","journal-title":"Genesis"},{"key":"1133_CR47","doi-asserted-by":"crossref","unstructured":"K.R. Kalari, A.A. Nair, J.D. Bhavsar, D.R. O\u2019Brien, J.I. Davila, M.A. Bockol, J.F. Nie, X.J. Tang, S. Baheti, J.B. Doughty et al., MAP-RSeq: Mayo analysis pipeline for RNA sequencing. BMC Bioinform. 15, (2014)","DOI":"10.1186\/1471-2105-15-224"},{"key":"1133_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"A. Dobin, C.A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson, T.R. Gingeras, STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 29, 15\u201321 (2013)","journal-title":"Bioinformatics"},{"key":"1133_CR49","doi-asserted-by":"crossref","unstructured":"Y. Liao, G.K. Smyth, W. Shi, The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, (2013)","DOI":"10.1093\/nar\/gkt214"},{"key":"1133_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"M.D. Robinson, D.J. McCarthy, G.K. Smyth, EdgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26, 139\u2013140 (2010)","journal-title":"Bioinformatics"},{"key":"1133_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1034\/j.1600-0676.2003.01707.x","volume":"23","author":"S Hanada","year":"2003","unstructured":"S. Hanada, M. Harada, H. Koga, T. Kawaguchi, E. Taniguchi, R. Kumashiro, T. Ueno, Y. Ueno, M. Ishii, S. Sakisaka et al., Tumor necrosis factor-\u03b1 and interferon-\u03b3 directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver Int. 23, 3\u201311 (2003)","journal-title":"Liver Int."},{"key":"1133_CR52","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11626-998-0106-x","volume":"34","author":"K Yahagi","year":"1998","unstructured":"K. Yahagi, M. Ishii, K. Kobayashi, Y. Ueno, Y. Mano, H. Niitsuma, T. Igarashi, T. Toyota, Primary culture of cholangiocytes from normal mouse liver. Vitro Cell. Dev-An. 34, 512\u2013514 (1998)","journal-title":"Vitro Cell. Dev-An"},{"key":"1133_CR53","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.18632\/oncotarget.23638","volume":"9","author":"SI Ilyas","year":"2018","unstructured":"S.I. Ilyas, S.R. Fischbach, S.F. Bronk, P. Hirsova, A. Krishnan, R. Dhanasekaran, J.B. Smadbeck, R.L. Smoot, G. Vasmatzis, G.J. Gores, YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget. 9, 5892\u20135905 (2018)","journal-title":"Oncotarget"},{"key":"1133_CR54","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1038\/s41467-018-07394-5","volume":"9","author":"WC Yuan","year":"2018","unstructured":"W.C. Yuan, B. Pepe-Mooney, G.G. Galli, M.T. Dill, H.T. Huang, M. Hao, Y. Wang, H. Liang, R.A. Calogero, F.D. Camargo, NUAK2 is a critical YAP target in liver cancer. Nat. Commun. 9, 4834 (2018)","journal-title":"Nat. Commun."},{"key":"1133_CR55","unstructured":"Y. Wang, X. Xu, D. Maglic, M.T. Dill, K. Mojumdar, P.K. Ng, K.J. Jeong, Y.H. Tsang, D. Moreno, V.H. Bhavana et al., Comprehensive molecular characterization of the hippo signaling pathway in cancer. Cell Rep 25, 1304\u20131317 e1305 (2018)"},{"key":"1133_CR56","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1172\/JCI59261","volume":"121","author":"Y Malato","year":"2011","unstructured":"Y. Malato, S. Naqvi, N. Sch\u00fcrmann, R. Ng, B. Wang, J. Zape, M.A. Kay, D. Grimm, H. Willenbring, Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J. Clin. Invest. 121, 4850\u20134860 (2011)","journal-title":"J. Clin. Invest."},{"key":"1133_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12935-022-02843-0","volume":"23","author":"T Gromowski","year":"2023","unstructured":"T. Gromowski, V. Lukacs-Kornek, J. Cisowski, Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination. Cancer Cell. Int. 23, 3 (2023)","journal-title":"Cancer Cell. Int."},{"key":"1133_CR58","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1172\/JCI59261","volume":"121","author":"Y Malato","year":"2011","unstructured":"Y. Malato, S. Naqvi, N. Schurmann, R. Ng, B. Wang, J. Zape, M.A. Kay, D. Grimm, H. Willenbring, Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J. Clin. Invest. 121, 4850\u20134860 (2011)","journal-title":"J. Clin. Invest."},{"key":"1133_CR59","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.semcdb.2012.05.004","volume":"23","author":"WJ Hong","year":"2012","unstructured":"W.J. Hong, K.L. Guan, The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell. Dev. Biol. 23, 785\u2013793 (2012)","journal-title":"Semin Cell. Dev. Biol."},{"key":"1133_CR60","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1002\/mc.23791","volume":"63","author":"X Ma","year":"2024","unstructured":"X. Ma, Y.Y. Zhou, R.P. Li, X.M. Ding, D.Y. Li, T.T. Pan, F.Q. Zhang, W.L. Li, Targeting Hippo\/YAP in intrahepatic cholangiocarcinoma: promising molecules in cancer therapy. Mol. Carcinogen. 63, 1866\u20131873 (2024)","journal-title":"Mol. Carcinogen"},{"key":"1133_CR61","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.celrep.2015.02.027","volume":"10","author":"J Fitamant","year":"2015","unstructured":"J. Fitamant, F. Kottakis, S. Benhamouche, H.S. Tian, N. Chuvin, C.A. Parachoniak, J.M. Nagle, R.M. Perera, M. Lapouge, V. Deshpande et al., YAP Inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell. Rep. 10, 1692\u20131707 (2015)","journal-title":"Cell. Rep."},{"key":"1133_CR62","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cell.2014.03.060","volume":"157","author":"D Yimlamai","year":"2014","unstructured":"D. Yimlamai, C. Christodoulou, G.G. Galli, K. Yanger, B. Pepe-Mooney, B. Gurung, K. Shrestha, P. Cahan, B.Z. Stanger, F.D. Camargo, Hippo pathway activity influences liver cell fate. Cell. 157, 1324\u20131338 (2014)","journal-title":"Cell"},{"key":"1133_CR63","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1073\/pnas.1517188113","volume":"113","author":"M Nishio","year":"2016","unstructured":"M. Nishio, K. Sugimachi, H. Goto, J. Wang, T. Morikawa, Y. Miyachi, Y. Takano, H. Hikasa, T. Itoh, S.O. Suzuki et al., Dysregulated YAP1\/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a\/1b-deficient mice. Proc. Natl. Acad. Sci. U S A 113, E71\u201380 (2016)","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"1133_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.21037\/hbsn-23-607","volume":"13","author":"MS Rezaee-Zavareh","year":"2024","unstructured":"M.S. Rezaee-Zavareh, E.K. Koltsova, Y. Hoshida, J.D. Yang, Primary liver cancer spectrum: current knowledge and the next steps. Hepatobiliary Surg. Nutr. 13, 157\u2013160 (2024)","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"1133_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","volume":"17","author":"AJ Craig","year":"2020","unstructured":"A.J. Craig, von J. Felden, T. Garcia-Lezana, S. Sarcognato, A. Villanueva, Tumour evolution in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 17, 139\u2013152 (2020)","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1133_CR66","first-page":"4101","volume":"22","author":"L Jiang","year":"2020","unstructured":"L. Jiang, J. Li, C. Zhang, Y. Shang, J. Lin, YAP\u2013mediated crosstalk between the Wnt and Hippo signaling pathways (Review). Mol. Med. Rep. 22, 4101\u20134106 (2020)","journal-title":"Mol. Med. Rep."},{"key":"1133_CR67","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2022.04.028","volume":"163","author":"Y Zhang","year":"2022","unstructured":"Y. Zhang, H. Xu, G. Cui, B. Liang, X. Chen, S. Ko, S. Affo, X. Song, Y. Liao, J. Feng et al., beta-Catenin sustains and is required for YES-associated protein oncogenic activity in cholangiocarcinoma. Gastroenterology. 163, 481\u2013494 (2022)","journal-title":"Gastroenterology"},{"key":"1133_CR68","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.cell.2012.11.026","volume":"151","author":"J Rosenbluh","year":"2012","unstructured":"J. Rosenbluh, D. Nijhawan, A.G. Cox, X. Li, J.T. Neal, E.J. Schafer, T.I. Zack, X. Wang, A. Tsherniak, A.C. Schinzel et al., beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 151, 1457\u20131473 (2012)","journal-title":"Cell"},{"key":"1133_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41586-018-0519-y","volume":"562","author":"M Seehawer","year":"2018","unstructured":"M. Seehawer, F. Heinzmann, L. D\u2019Artista, J. Harbig, P.F. Roux, L. Hoenicke, H. Dang, S. Klotz, L. Robinson, G. Dor\u00e9 et al., Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 562, 69\u2013 (2018)","journal-title":"Nature"},{"key":"1133_CR70","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/jgm.921","volume":"8","author":"MG Sebesty\u00e9n","year":"2006","unstructured":"M.G. Sebesty\u00e9n, V.G. Budker, T. Budker, V.M. Subbotin, G.F. Zhang, S.D. Monahan, D.L. Lewis, S.C. Wong, J.E. Hagstrom, J.A. Wolff, Mechanism of plasmid delivery by hydrodynamic tail vein injection.: I.: hepatocyte uptake of various molecules. J. Gene Med. 8, 852\u2013873 (2006)","journal-title":"J. Gene Med."},{"key":"1133_CR71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jhep.2009.02.022","volume":"51","author":"AC Piscaglia","year":"2009","unstructured":"A.C. Piscaglia, T.D. Shupe, G. Pani, V. Tesori, A. Gasbarrini, B.E. Petersen, Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J. Hepatol. 51, 77\u201392 (2009)","journal-title":"J. Hepatol."},{"key":"1133_CR72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1290\/1071-2690(2001)037<0017:COANRC>2.0.CO;2","volume":"37","author":"R Gil-Benso","year":"2001","unstructured":"R. Gil-Benso, A. Martinez-Lorente, A. Pellin-Perez, S. Navarro-Fos, M.A. Gregori-Romero, C. Carda, R. Callaghan, A. Peydro-Olaya, A. Llombart-Bosch, Characterization of a new rat cell line established from 2\u2019AAF-induced combined hepatocellular cholangiocellular carcinoma. Vitro Cell. Dev. Biol. Anim. 37, 17\u201325 (2001)","journal-title":"Vitro Cell. Dev. Biol. Anim."},{"key":"1133_CR73","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0168-8278(96)80161-9","volume":"24","author":"H Yano","year":"1996","unstructured":"H. Yano, A. Iemura, M. Haramaki, S. Momosaki, S. Ogasawara, K. Higaki, M. Kojiro, A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J. Hepatol. 24, 413\u2013422 (1996)","journal-title":"J. Hepatol."},{"key":"1133_CR74","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/hep.1840070322","volume":"7","author":"T Murakami","year":"1987","unstructured":"T. Murakami, H. Yano, M. Maruiwa, S. Sugihara, M. Kojiro, Establishment and characterization of a human combined hepatocholangiocarcinoma cell line and its heterologous transplantation in nude mice. Hepatology. 7, 551\u2013556 (1987)","journal-title":"Hepatology"},{"key":"1133_CR75","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41556-022-00848-5","volume":"24","author":"H Li","year":"2022","unstructured":"H. Li, B.K. Wu, M. Kanchwala, J. Cai, L. Wang, C. Xing, Y. Zheng, Pan, D. YAP\/TAZ drives cell proliferation and tumour growth via a polyamine-eIF5A hypusination-LSD1 axis. Nat. Cell. Biol. 24, 373\u2013383 (2022)","journal-title":"Nat. Cell. Biol."},{"key":"1133_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","volume":"20","author":"IM Moya","year":"2019","unstructured":"I.M. Moya, G. Halder, Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine. Nat. Rev. Mol. Cell. Biol. 20, 211\u2013226 (2019)","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"1133_CR77","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/febs.13665","volume":"283","author":"I Fabregat","year":"2016","unstructured":"I. Fabregat, J. Moreno-Caceres, A. Sanchez, S. Dooley, B. Dewidar, G. Giannelli, Ten P. Dijke, Consortium, I.-L. TGF-beta signalling and liver disease. FEBS J. 283, 2219\u20132232 (2016)","journal-title":"FEBS J."},{"key":"1133_CR78","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"H. Nakamura, Y. Arai, Y. Totoki, T. Shirota, A. Elzawahry, M. Kato, N. Hama, F. Hosoda, T. Urushidate, S. Ohashi et al., Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003\u2013 (2015)","journal-title":"Nat. Genet."},{"key":"1133_CR79","doi-asserted-by":"crossref","unstructured":"S.S. Zou, J.R. Li, H.B. Zhou, C. Frech, X.L. Jiang, J.S.C. Chu, X.Y. Zhao, Y.Q. Li, Q.M. Li, H. Wang et al., Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, (2014)","DOI":"10.1038\/ncomms6696"},{"key":"1133_CR80","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","volume":"25","author":"J Chen","year":"2019","unstructured":"J. Chen, J.A. Gingold, X.P. Su, Immunomodulatory TGF-\u03b2 signaling in hepatocellular carcinoma. Trends Mol. Med. 25, 1010\u20131023 (2019)","journal-title":"Trends Mol. Med."},{"key":"1133_CR81","doi-asserted-by":"publisher","first-page":"1432423","DOI":"10.3389\/fonc.2024.1432423","volume":"14","author":"R Gujarathi","year":"2024","unstructured":"R. Gujarathi, J.W. Franses, A. Pillai, C.Y. Liao, Targeted therapies in hepatocellular carcinoma: past, present, and future. Front. Oncol. 14, 1432423 (2024)","journal-title":"Front. Oncol."},{"key":"1133_CR82","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/liv.14113","volume":"39","author":"S Faivre","year":"2019","unstructured":"S. Faivre, A. Santoro, R.K. Kelley, E. Gane, C.E. Costentin, I. Gueorguieva, C. Smith, A. Cleverly, M.M. Lahn, E. Raymond et al., Novel transforming growth factor beta receptor I kinase inhibitor Galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 39, 1468\u20131477 (2019)","journal-title":"Liver Int."},{"key":"1133_CR83","doi-asserted-by":"publisher","first-page":"e00056","DOI":"10.14309\/ctg.0000000000000056","volume":"10","author":"RK Kelley","year":"2019","unstructured":"R.K. Kelley, E. Gane, E. Assenat, J. Siebler, P.R. Galle, P. Merle, I.O. Hourmand, A. Cleverly, Y. Zhao, I. Gueorguieva et al., A phase 2 study of Galunisertib (TGF-beta1 receptor type I Inhibitor) and Sorafenib in patients with advanced hepatocellular carcinoma. Clin. Transl Gastroenterol. 10, e00056 (2019)","journal-title":"Clin. Transl Gastroenterol."},{"key":"1133_CR84","doi-asserted-by":"publisher","first-page":"e0183932","DOI":"10.1371\/journal.pone.0183932","volume":"12","author":"AM Lustri","year":"2017","unstructured":"A.M. Lustri, Di S. Matteo, A. Fraveto, D. Costantini, A. Cantafora, C. Napoletano, M.C. Bragazzi, F. Giuliante, De A.M. Rose, P.B. Berloco et al., TGF-beta signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures. Plos One. 12, e0183932 (2017)","journal-title":"Plos One"},{"key":"1133_CR85","doi-asserted-by":"crossref","unstructured":"P. Papoutsoglou, C. Louis, C. Coulouarn, Transforming growth factor-beta (TGFbeta) signaling pathway in cholangiocarcinoma. Cells-Basel 8, (2019)","DOI":"10.3390\/cells8090960"},{"key":"1133_CR86","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/HEP.0000000000000365","volume":"78","author":"C Yoo","year":"2023","unstructured":"C. Yoo, M.M. Javle, V. Mata, H. de Braud, F. Trojan, J. Raoul, J.L. Kim, J.W. Ueno, M. Lee, C.K. Hijioka, Phase 2 trial of bintrafusp Alfa as second-line therapy for patients with locally advanced\/metastatic biliary tract cancers. Hepatology. 78, 758\u2013770 (2023)","journal-title":"Hepatology"},{"key":"1133_CR87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-024-02052-3","volume":"9","author":"L Yi","year":"2024","unstructured":"L. Yi, H. Pan, Z. Ning, L. Xu, H. Zhang, L. Peng, Y. Liu, Y. Yang, W. Si, Y. Wang et al., Clinical and biomarker analyses of SHR-1701 combined with Famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial. Signal. Transduct. Target. Ther. 9, 347 (2024)","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1133_CR88","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/HEP.0000000000000965","volume":"81","author":"DY Oh","year":"2025","unstructured":"D.Y. Oh, M. Ikeda, C.K. Lee, C. Rojas, C.H. Hsu, J.W. Kim, L. Shen, J. Furuse, J.O. Park, M. Borad et al., Bintrafusp Alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2\/3 trial. Hepatology. 81, 823\u2013836 (2025)","journal-title":"Hepatology"},{"key":"1133_CR89","doi-asserted-by":"publisher","first-page":"e13736","DOI":"10.1111\/cts.13736","volume":"17","author":"D Robbrecht","year":"2024","unstructured":"D. Robbrecht, J.J. Grob, O. Bechter, M. Simonelli, B. Doger, I. Borbath, M.O. Butler, T. Cheng, P.M. Romano, E. Pons-Tostivint et al., Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFbeta) inhibitor SAR439459 as monotherapy and in combination with Cemiplimab in a phase I clinical study in patients with advanced solid tumors. Clin. Transl Sci. 17, e13736 (2024)","journal-title":"Clin. Transl Sci."},{"key":"1133_CR90","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/hep.26762","volume":"59","author":"AE Sirica","year":"2014","unstructured":"A.E. Sirica, G.J. Gores, Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology. 59, 2397\u20132402 (2014)","journal-title":"Hepatology"},{"key":"1133_CR91","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","volume":"73","author":"L Fabris","year":"2021","unstructured":"L. Fabris, K. Sato, G. Alpini, M. Strazzabosco, The tumor microenvironment in cholangiocarcinoma progression. Hepatology. 73, 75\u201385 (2021)","journal-title":"Hepatology"},{"key":"1133_CR92","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"J.M. Llovet, F. Castet, M. Heikenwalder, M.K. Maini, V. Mazzaferro, D.J. Pinato, E. Pikarsky, A.X. Zhu, R.S. Finn, Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172 (2022)","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1133_CR93","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"J.M. Banales, J.J.G. Marin, A. Lamarca, P.M. Rodrigues, S.A. Khan, L.R. Roberts, V. Cardinale, G. Carpino, J.B. Andersen, C. Braconi et al., Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastro Hepat. 17, 557\u2013588 (2020)","journal-title":"Nat. Rev. Gastro Hepat."},{"key":"1133_CR94","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41419-020-2509-x","volume":"11","author":"G Wang","year":"2020","unstructured":"G. Wang, Q. Wang, N. Liang, H. Xue, T. Yang, X. Chen, Z. Qiu, C. Zeng, T. Sun, W. Yuan et al., Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell. Death Dis. 11, 313 (2020)","journal-title":"Cell. Death Dis."},{"key":"1133_CR95","doi-asserted-by":"publisher","first-page":"856247","DOI":"10.3389\/fimmu.2022.856247","volume":"13","author":"R Caire","year":"2022","unstructured":"R. Caire, E. Dalix, M. Chafchafi, M. Thomas, M.T. Linossier, M. Normand, A. Guignandon, L. Vico, H. Marotte, YAP transcriptional activity dictates cell response to TNF in vitro. Front. Immunol. 13, 856247 (2022)","journal-title":"Front. Immunol."},{"key":"1133_CR96","doi-asserted-by":"publisher","first-page":"1204033","DOI":"10.3389\/fcell.2023.1204033","volume":"11","author":"L Chen","year":"2023","unstructured":"L. Chen, X. Jin, J. Ma, B. Xiang, X. Li, YAP at the progression of inflammation. Front. Cell. Dev. Biol. 11, 1204033 (2023)","journal-title":"Front. Cell. Dev. Biol."},{"key":"1133_CR97","doi-asserted-by":"crossref","unstructured":"Y.H. Xue, W. Mars, W. Bowen, J.Y. Tao, A. Oft, J. Stoops, G. Michalopoulos, p-Ezrin (Thr567) synergizes with Akt signaling to accelerate Yap mediated cholangiocarcinogenesis, but correlates with favorable prognosis in human intrahepatic cholangiocarcinoma(ICC) patients. Faseb J. 35, (2021)","DOI":"10.1096\/fasebj.2021.35.S1.04062"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-025-01133-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01133-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:02:22Z","timestamp":1766584942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-025-01133-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1007\/s13402-025-01133-x","relation":{},"ISSN":["2211-3436"],"issn-type":[{"type":"electronic","value":"2211-3436"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with a protocol approved by the Mayo Clinic Institutional Animal Care and Use Committee (A00004395).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}